Gilead Sciences, Inc.
NEWS
As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
Since Allogene Therapeutics launched in April the company has been rapidly expanding its leadership team as it drives forward with a mission of developing allogeneic CAR-T therapies.
Reportedly, Madrigal Pharmaceuticals is considering a sale. After receiving interest from other big drug companies, the nine-employee company is evaluating its options.
The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.
Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.
Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
JOBS
IN THE PRESS